Skip to main content

Fiscal Wizard · Single-issue tearsheet

BSX / Aug 13, 2026 Run #13794

BSX

Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Composite verdict

F 28.7 / 100
Bearish setup · Mean Reversion 13 drivers · 2 gates blocking
  • Wedge Pattern
  • RSI-14 Threshold
  • Williams %R
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 9th of 10 in Medical Devices

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Neutral 48Mean-reversion Bearish 7

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -61%
Asset value $16.72Earnings power value $17.34Price $51.42

Priced above its no-growth earnings power value ($17.34/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

57.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 79
OCF to Net Income 0
Greenblatt ROC 77
Cash Conversion Cycle 0

Technicals Bearish

0.2 / 100

Bearish setup leads (Wedge Pattern, RSI-14 Threshold, Williams %R); bulls gated by guards. · 44 signals shown.

Strongest
Weakest
Wedge Pattern 9
Williams %R 10
RSI-14 Threshold 12

Risk Gates

2 blocking 3 caution

2 guards active, 25 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Interest Coverage Caution

Weak interest coverage blocks bullish signals — debt-service risk.

MA Crossover Bullish counter-regime

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BSX.